Table 1.
Multivalent meningococcal conjugate vaccines licensed or in clinical trials worldwide. The multivalent conjugate vaccines containing at least two Men serogroups are listed here
| Commercial trade name/clinical trial phase | Target serogroup | Manufacturer |
|---|---|---|
| MengNa Kang | AC (a) | Beijing Luzhu (subsidiary of ChongquingZhifei) |
| Nao Man King | Xiangrui (also known as Beijing Sanroad) | |
| Wo Er Kang | Yunnan Walvax | |
| MeningACon | BeijingZhifei Lvzhu Biopharmaceutical | |
| N/A | Royal Wuxi | |
| Menactra | ACWY | Sanofi Pasteur |
| Menveo | GSK Vaccines | |
| Nimenrix | Pfizer | |
| MenQuadfi | Sanofi Pasteur | |
| Phase 1/2 | ACWYX | Serum Institute of India/PATH |
| Phase 3 | ABCWY (b) | GSK Vaccines |
| Phase 3 | Pfizer |
(a) For national vaccination; (b) composed of glycoconjugates combined with other antigens